Treatment of intraocular pressure elevation after photorefractive keratectomy.
OBJECTIVE
To study the effect of timolol maleate, dorzolamide, or a combination of both in post photorefractive keratectomy (PRK) eyes with an elevated intraocular pressure (IOP) after topical steroid administration.


METHODS
Refractive Surgery Outpatient Department, 1st Department of Ophthalmology, Semmelweis University, Budapest, Hungary.


METHODS
Forty-five patients with elevated IOP were randomly enrolled in 3 groups: Group 1 received timolol maleate 0.5% twice a day; Group 2 received timolol maleate 0.5% twice a day and dorzolamide 2% 3 times a day; and Group 3 received only topical dorzolamide 2% 3 times a day. Intraocular pressure was measured 3 days and 1, 3, and 6 weeks after the antiglaucoma medication was started.


RESULTS
The mean preoperative IOP was 15.25 mm Hg +/- 1.28 (SD). Following administration of topical fluorometholone, the IOP increased a mean of 27.39 +/- 2.88 mm Hg. Six weeks after the antiglaucoma therapy was started, the mean IOP reduction was 6.6 mm Hg in Group 1, 8.86 mm Hg in Group 2, and 4.64 mm Hg in Group 3.


CONCLUSIONS
A combination therapy of timolol 0.5% and dorzolamide 2% was most effective in treating secondary IOP elevation after PRK. Dorzolamide alone did not adequately control secondary post-PRK IOP elevation.
Nagy
Z Z
ZZ
1st Department of Ophthalmology, Semmelweis Medical University, Tömö u. 25-29, H-1083 Budapest, Hungary.
Szabó
A
A
Krueger
R R
RR
Süveges
I
I
D000287:Administration, Topical; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D002257:Carbonic Anhydrase Inhibitors / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005469:Fluorometholone / Q000008:administration & dosage; D005938:Glucocorticoids; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D054018:Lasers, Excimer; D008297:Male; D009798:Ocular Hypertension / Q000188:drug therapy* / Q000209:etiology; D009883:Ophthalmic Solutions; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D011446:Prospective Studies; D013449:Sulfonamides / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*; D014065:Tonometry, Ocular
D000319:Adrenergic beta-Antagonists; D000893:Anti-Inflammatory Agents; D002257:Carbonic Anhydrase Inhibitors; D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D013449:Sulfonamides; D013876:Thiophenes; D013999:Timolol; C062765:dorzolamide; D005469:Fluorometholone